Claims for Patent: 11,426,404

Summary for Patent: 11,426,404

Title:	Dosing of KRAS inhibitor for treatment of cancers
Abstract:	Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.
Inventor(s):	Henary; Haby (Moorpark, CA), Lipford; James Russell (Thousand Oaks, CA), Cee; Victor J. (Thousand Oaks, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	15/930,606
Patent Claims:	1. A method of treating KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in a subject in need thereof, comprising orally administering to the subject 960 mg once daily of a compound, wherein the compound is ##STR00016## 2. The method of claim 1, wherein the subject, prior to first administering the compound, has undergone at least one systemic cancer therapy. 3. The method of claim 1, wherein the compound is administered as a tablet. 4. The method of claim 2, wherein the compound is administered as a tablet. 5. The method of claim 1, wherein the subject is an adult. 6. The method of claim 2, wherein the subject is an adult. 7. The method of claim 3, wherein the subject is an adult. 8. The method of claim 4, wherein the subject is an adult. 9. A method of treating KRAS G12C-mutated non-small cell lung cancer in a subject in need thereof, comprising administering to the subject 960 mg once daily of a compound, wherein the compound is ##STR00017## 10. The method of claim 9, wherein the subject, prior to first administering the compound, has undergone at least one systemic cancer therapy. 11. The method of claim 9, wherein the compound is administered as a tablet. 12. The method of claim 10, wherein the compound is administered as a tablet. 13. The method of claim 11, wherein the compound is administered orally. 14. The method of claim 12, wherein the compound is administered orally. 15. The method of claim 9, wherein the subject is an adult. 16. The method of claim 10, wherein the subject is an adult. 17. The method of claim 11, wherein the subject is an adult. 18. The method of claim 12, wherein the subject is an adult. 19. The method of claim 13, wherein the subject is an adult. 20. The method of claim 14, wherein the subject is an adult. 21. A method of treating KRAS G12C-mutated colorectal cancer in a subject in need thereof, comprising administering to the subject 960 mg once daily of a compound, wherein the compound is ##STR00018## 22. The method of claim 21, wherein the subject, prior to first administering the compound, has undergone at least one systemic cancer therapy. 23. The method of claim 21, wherein the subject, prior to first administering the compound, has undergone at least two systemic cancer therapies. 24. The method of claim 21, wherein the compound is administered as a tablet. 25. The method of claim 22, wherein the compound is administered as a tablet. 26. The method of claim 23, wherein the compound is administered as a tablet. 27. The method of claim 24, wherein the compound is administered orally. 28. The method of claim 25, wherein the compound is administered orally. 29. The method of claim 26, wherein the compound is administered orally. 30. The method of claim 21, wherein the subject is an adult. 31. The method of claim 22, wherein the subject is an adult. 32. The method of claim 23, wherein the subject is an adult. 33. The method of claim 24, wherein the subject is an adult. 34. The method of claim 25, wherein the subject is an adult. 35. The method of claim 26, wherein the subject is an adult. 36. A method of treating KRAS G12C-mutated pancreatic cancer in a subject in need thereof, comprising administering to the subject 960 mg once daily of a compound, wherein the compound is ##STR00019## 37. The method of claim 36, wherein the subject, prior to first administering the compound, has undergone at least one systemic cancer therapy. 38. The method of claim 36, wherein the compound is administered as a tablet. 39. The method of claim 37, wherein the compound is administered as a tablet. 40. The method of claim 38, wherein the compound is administered orally. 41. The method of claim 39, wherein the compound is administered orally. 42. The method of claim 36, wherein the subject is an adult. 43. The method of claim 37, wherein the subject is an adult. 44. The method of claim 38, wherein the subject is an adult. 45. The method of claim 39, wherein the subject is an adult. 46. The method of claim 40, wherein the subject is an adult. 47. The method of claim 41, wherein the subject is an adult.